当前位置： SCI文献检索 > CANCER期刊下所有文献 > Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence.

Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence.

Abstract：

BACKGROUND:CD133 is a specific surface marker for bone marrow-derived circulating endothelial progenitors, which are vital in postnatal physiologic and pathologic (eg, tumor) angiogenesis. In this study, the authors examined whether increased levels of expression of CD133 messenger RNA (mRNA) in peripheral blood predicted disease recurrence in patients with colon cancer. METHODS:Semiquantitative real-time reverse transcriptase-polymerase chain reaction analysis was used to quantify CD133 mRNA levels in peripheral blood mononuclear cells from patients with colon cancer. The assay was developed first and tested at laboratory A (n = 34) and then was validated independently at laboratory B (n = 66). All patients were enrolled between February 2002 and December 2003. A central statistician performed the analysis. RESULTS:At laboratory A, the median CD133 mRNA level was elevated in patients with recurrent disease (4.2; range, 0.017-106.9) compared with patients without recurrence (0.0017; range, 0.0-9.51; P < .001), leading to a 14.6 odds ratio of recurrence (95% confidence interval [95% CI], 1.7-126; P = .004). At laboratory B, it was confirmed that elevated CD133 mRNA levels at a cutoff point >or=4.79 versus <4.79 were associated with an odds ratio of 22.6 for recurrence (95% CI, 1.7-291.2; P = .02). By comparison, the odds ratio for recurrence was 17.2 (95% CI, 1.8-164; P = .01) for patients with stage III-IV disease versus stage I-II disease according to the Tumor, Lymph Node, Metastasis (TNM) classification. An association also was observed between elevated carcinoma embryonic antigen levels (P = .03; 1-sided) and decreased survival (P = .035; 1-sided) with a CD133 mRNA cutoff level of >or=4.79. CONCLUSIONS:Elevated CD133 mRNA levels at >or=4.79 predicted colon cancer recurrence independent of TNM stage IV disease. Larger prospective studies comparing the current assay with standardized methodology are warranted.

journal_name

Cancer

journal_title

Cancer

authors

Lin EH,Hassan M,Li Y,Zhao H,Nooka A,Sorenson E,Xie K,Champlin R,Wu X,Li D

doi

10.1002/cncr.22774

subject

Has Abstract

pub_date

2007-08-01 00:00:00

pages

534-42

issue

eissn

0008-543X

issn

1097-0142

journal_volume

110

pub_type

杂志文章

在线工具

Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence.